

# CITATION REPORT

List of articles citing

## Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors

DOI: 10.1371/journal.pone.0134969  
PLoS ONE, 2015, 10, e0134969.

**Source:** <https://exaly.com/paper-pdf/61047293/citation-report.pdf>

**Version:** 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
21	Targeting metastasis. <i>Nature Reviews Cancer</i> , <b>2016</b> , 16, 201-18	31.3	786
20	Epigenetics in endometrial carcinogenesis - part 1: DNA methylation. <i>Epigenomics</i> , <b>2017</b> , 9, 737-755	4.4	15
19	The expression of ER, PR in endometrial cancer and analysis of their correlation with ERK signaling pathway. <i>Cancer Biomarkers</i> , <b>2017</b> , 21, 145-149	3.8	3
18	Cancer metastasis: enactment of the script for human reproductive drama. <i>Cancer Cell International</i> , <b>2017</b> , 17, 51	6.4	3
17	Isoform specificity of progesterone receptor antibodies. <i>Journal of Pathology: Clinical Research</i> , <b>2017</b> , 3, 227-233	5.3	10
16	Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , <b>2018</b> , 28, 505-513	3.5	17
15	ER and PR expression and survival after endometrial cancer. <i>Gynecologic Oncology</i> , <b>2018</b> , 148, 258-266	4.9	29
14	Phenotypic Intratumoral Heterogeneity of Endometrial Carcinomas. <i>International Journal of Gynecological Pathology</i> , <b>2018</b> , 37, 154-166	3.2	2
13	Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer. <i>Endocrine-Related Cancer</i> , <b>2018</b> ,	5.7	15
12	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. <i>Gynecologic Oncology</i> , <b>2019</b> , 154, 29-37	4.9	18
11	Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 359	5.3	39
10	Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?. <i>Current Problems in Cancer</i> , <b>2020</b> , 44, 100498	2.3	13
9	Metapristone (RU486-derivative) inhibits endometrial cancer cell progress through regulating miR-492/Klf5/Nrf1 axis. <i>Cancer Cell International</i> , <b>2021</b> , 21, 29	6.4	2
8	Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 225, 407.e1-407.e16	6.4	2
7	Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
6	Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions. <i>Hormones and Cancer</i> , <b>2019</b> , 10, 51-63	5	84
5	Tumor board presentation of a woman with metastatic, hormone receptor-positive, mismatch repair-deficient endometrial cancer.. <i>Ca-A Cancer Journal for Clinicians</i> , <b>2022</b> ,	220.7	0

4 Table\_1.DOCX. **2019**,

3 Hormone therapy in endometrial cancer survivors: time for a change. 1-2

○

2 The effect of progestin therapy in advanced and recurrent endometrial cancer: a systematic review and meta-analysis.

○

1 Quantification of Women Who Could Benefit from Hormone Therapy after Endometrial Cancer Treatment: An Analysis of SEER Data. **2022**, 29, 9215-9223

○